Turk J Haematol 2017 Jul 27

Retrospective evaluation of hairy cell leukemia patients treated with 3 different first-line treatment modalities in the last two decades: a single center experience.

Öngören Ş, Eşkazan AE, Berk S, Elverdi T, Salihoğlu A, Ar MC, Başlar Z, Aydın Y, Tüzüner N, Soysal T.
In this study, we retrospectively analysed the clinical outcome, treatment responses, infectious complications and survival rates of seventy-one hairy cell leukemia (HCL) cases.
l="OBJECTIVE" NlmCategory="OBJECTIVE">In this study, we retrospectively analysed the clinical outcome, treatment responses, infectious complications and survival rates of seventy-one hairy cell leukemia (HCL) cases.

MATERIALS AND METHODS:

Sixty-six patients received a first-line treatment, and 2-chlorodeoxyadenosine (cladribine-2-CdA) was administered in thirty-one, nineteen patients received interferon-alpha (INF-α), splenectomy was performed in 16 cases, and rituximab was used in one.

RESULTS:

Although the highest overall response rate (ORR) was observed in patients receiving upfront 2-CdA, ORRs were comparable in 2-CdA, INF-α, and splenectomy subgroups. And relapse rates were significantly lower in patients who received first-line 2-CdA. Progression-free survival (PFS) rate with 2-CdA was significantly higher than those with INF-α and splenectomy, but we found similar overall survival (OS) rates with all three upfront treatment modalities. Infections including tuberculosis were a major problem.

CONCLUSION:

Although purine analogues improved the ORRs and PFS there is still much to go with regard to OS and relapsed/refractory disease in patients with HCL.